Healing · 5mg × 10 vials
it tells cells to move into damaged tissue, lay down new structure, grow blood supply to it, and quiet the inflammation around it.
TB-500 is the N-acetyl active fragment of Thymosin Beta-4 (TB-4), a naturally occurring 43-amino-acid peptide found in nearly every cell in the body and present at especially high concentrations in wound fluid and platelets. Its primary mechanism is actin sequestration: TB-4 binds G-actin monomers and regulates the assembly of the actin cytoskeleton, which is what lets cells migrate to sites of injury, build new tissue, and form new blood vessels. Downstream of that, three things matter for healing: it upregulates VEGF and other angiogenic factors (new capillary growth to bring blood/oxygen to damaged tissue), it activates progenitor and endothelial cells (cell migration and proliferation into the wound bed), and it dampens pro-inflammatory cytokines like TNF-alpha and NF-kB signaling (less collateral inflammation, faster resolution). In animal models it accelerates wound closure, increases collagen deposition, and in cardiac infarct models recruits epicardial progenitor cells that migrate into damaged myocardium. In plain language: it tells cells to move into damaged tissue, lay down new structure, grow blood supply to it, and quiet the inflammation around it. This is the layer BPC-157 doesn't fully cover. BPC works mostly locally on angiogenesis via VEGFR2 and growth-factor receptor expression. TB-500 works systemically on actin-driven cell migration and is why the "BPC + TB" healing stack became the standard community combo. They don't compete on pathway, they layer.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
This is the protocol Jordan walks customers through in DMs. 10 mg vial + 2 ml BAC = 5 mg/ml, so 2.5 mg = 0.5 ml = 50 IU on a U-100 syringe. Most beginners are doing this for joint/tendon/soft-tissue recovery and pair it with BPC-157 from day one. Effect is gradual - don't expect overnight, expect noticeable improvement 2-4 weeks in.
This is the standard band for someone with an actual injury (torn meniscus recovery, post-surgical, chronic tendon issue). 10 mg vial reconstituted with 2 ml BAC = 5 mg/ml, so 2.5 mg = 0.5 ml = 50 IU twice weekly = 5 mg/wk total. Most customers in this band are also running BPC-157 250-500 mcg daily in the same syringe. The 10 mg single vial size is the workhorse SKU because it's exactly 2 weeks of loading or 4-5 weeks of maintenance.
Top-end protocols come from horse racing / equine use of TB-500 (where dosing is much higher relative to body weight and the recovery results made it famous in the first place) and from RegeneRx's Phase 2 cardiac trial which used ~42 mg total dose IV. Community advanced users rarely exceed 10 mg/wk because returns flatten. Pair with BPC-157 1-2 mg/day at this level. Don't run more than 16 weeks straight without a break - receptor tolerance isn't a documented issue but the convention is to give the system 4 weeks off to reset.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://pubmed.ncbi.nlm.nih.gov/16183326/) - foundational mechanism review by the field's lead researchers
Read study ↗PubMedCrockford D et al - Thymosin beta-4: structure, function, and biological properties supporting current and future clinical applications, Ann NY Acad Sci 2010comprehensive properties review including wound healing, cardiac repair, neuroprotection
Read study ↗PubMedBock-Marquette I et al - Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair, Nature 2004the seminal cardiac repair paper that launched RegeneRx Phase 2
Read study ↗PubMedSmart N et al - Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization, Nature 2007progenitor cell mobilization mechanism
Read study ↗PubMedSosne G et al - Thymosin beta-4 promotes corneal wound healing and decreases inflammation in vivo, Exp Eye Res 2001dry eye / corneal indication
Read study ↗PubMedRuff D et al - Safety, pharmacokinetics, and pharmacodynamics of recombinant human Thymosin beta-4 in healthy volunteers, Ann NY Acad Sci 2010Phase 1 human PK/safety
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Lethargy / fatigue in the first week: most-reported sensation. r/Peptides and PeptideHQ users describe a "drag" or "groggy" feeling during the first 5-10 days, especially at loading doses. Resolves on its own.
Mild dizziness or lightheadedness: reported by a minority, usually first injection or two. Settles.
Injection site soreness: common with subq, especially near a localized injury site.
Vivid dreams: occasionally reported in community, no mechanism, no formal data.
"Old injury flare-up" sensation: some users describe transient achiness in previously-healed injury sites during the loading phase, framed by community as "the body remembering and re-healing." Not documented, anecdotal.
- Divergence: Community reports first-week fatigue at a rate (~30-40% of users mention it on r/Peptides threads) that doesn't appear in the limited human trial data. The trials used IV cardiac dosing in sick patients, so the comparison is apples-to-oranges. For healthy users running SubQ loading doses, expect a mild "blah" week 1, plan around it.
Route: SubQ injection (IM also used, especially for muscle/joint-localized work; SubQ is the community default)
Injection site: abdomen, outer thigh, or near the injury for localized work (joint-adjacent SubQ, not intra-articular). Rotate sites if injecting systemically.
Storage: refrigerated, ~28 days after reconstitution. Lyophilized vials keep refrigerated long-term, room temp acceptable for shipping windows.
Notes: Can be combined into the same syringe as BPC-157 - same site, same draw, no interaction, this is what most experienced users do to consolidate injections. Don't shake the vial, swirl gently. Solution should be clear; cloudiness means a bad reconstitution or contamination, do not use. Time of day doesn't matter for TB-500 (unlike BPC which some users dose pre-bed). The slow systemic half-life means consistency week-to-week matters more than timing within a day.